Table 1.
Study characteristics.
| Phases | |||
|---|---|---|---|
| Phase 1 | 3 | ||
| Phase 1/2 | 6 | ||
| Phase 3 | 1 | ||
| Recruitment/enrollment status | |||
| Recruiting | 7 | Enroll by invitation | 3 |
| Completed | 1 | ||
| Active, not recruiting | 2 | ||
| Suspended | 1 | ||
| Enrollment | 3 to 50 patients | Enrollment | 85 to 94 patients |
| Farthest out completion date | 2035 | Farthest out completion date | 2039 |
| Population | |||
| Age | 3 to no upper limit | Age | No limit |
| Genders | All; one did not state | Genders | All |
| Location | |||
| Multinational | 2 | Multinational | 3 |
| US-based | 8 | ||
| France-based | 1 | ||
| Inclusion Criteria | |||
| Severe SCD | 10 | Treated with drug product | 3 |
| Hydroxyurea failure | 7 | ||
| Hydroxyurea willingness to DC | 2 | ||
| Hydroxyurea not mentioned | 2 |